

Advancing bio-printing of living cells for regenerative medicine

Horizon Europe

● IN ATTESA

Codice
HORIZON-HLTH-2027-03-TOOL-02

Ambito
Internazionale

Località
Europa

Curatore
Marlene Faria

DETTAGLI FINANZIARI

Tipo di supporto
Fondo perduto

Tasso Massimo di Finanziamento
100%

Budget
39.3M€

Valore di Progetto Ammissibile
7M€ - 10M€

DATE E SCADENZE

Data di Pubblicazione
Non definita

Data di Apertura
3 giugno 2027

Fase unica
16 settembre 2027 alle ore 17:00 GMT+2

DESCRIZIONE

Objectives

This topic aims to advance functional 3D bioprinting of living cells for regenerative medicine , supporting the translation of promising preclinical approaches into clinically relevant solutions. Projects should develop complete bioprinting units capable of producing personalised, tissue-specific living constructs for the repair or regeneration of damaged tissues and internal organs.

The expected results should provide biomedical researchers with integrated bioprinting systems, give healthcare professionals evidence on their safe and effective use, and offer healthcare providers new tools for conditions with unmet medical needs. Patients should ultimately benefit from regenerative solutions adapted to their individual anatomy and clinical condition.

Funding

Funding is provided under a Horizon Europe Research and Innovation Action (RIA) . The topic has an indicative budget of €39.3 million , with approximately four projects expected to be funded. The anticipated EU contribution ranges between €7 million and €10 million per project , although proposals requesting different amounts may be considered where appropriately justified.

As a Research and Innovation Action, projects may receive funding of up to 100% of eligible costs , in accordance with Horizon Europe rules. The official Work Programme indicates a single-stage procedure , opening on 3 June 2027 and closing on 16 September 2027 .

SPESE AMMISSIBILI

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs

IDONEITÀ

Modalità di Candidatura

Aggregata / Partenariato

Settori Idonei

- Salute e Life Sciences
- ICT e Software

Tipologie Aziendali

- Microimpresa
- PMI
- Small Mid-Cap
- Mid-Cap
- Grande impresa
- Enti privati non profit
- Enti pubblici

Tipi di Azione

- Research and innovation
- Digital technology development
- Biomedical tool development
- AI-based health solutions

■ Health data integration

DETTAGLI PROGRAMMA UE

ID Bando

HORIZON-HLTH-2027-03-TOOL-02

Cluster

Health

Destinazione

D5. Developing and using new tools, technologies and digital solutions for a healthy society

Modalità di Presentazione

Single-stage

Contributo UE

Around €7,000,000.00 to €10,000,000.00 per project

Progetti Previsti

4

Regola del Tasso di Finanziamento

Up to 100% of eligible costs for Research and Innovation Actions (RIA)

LINK UFFICIALI

Regolamento Ufficiale

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-03-TOOL-02?order=DESC&pageNumber=1&pageSize=50&sortBy=relevance&keywords=HORIZON-HLTH-2027-03-TOOL-02&isExactMatch=true&status=31094501,31094502,31094503>

Pagina Grantavia

<https://grantavia.com/it/incentives/advancing-bio-printing-of-living-cells-for-regenerative-medicine>

Prenota un incontro

<https://bookings.cloud.microsoft/book/Prenotaunappuntamento@epsa.com/?ismsaljsauthenabed>